Xtandi + ADT slow disease-progression in mHSPC compared to darolutamide + ADT

ASTRO updates guideline on shorter-course radiation therapy for localized prostate cancer

An updated clinical guideline from the American Society for Radiation Oncology provides evidence-based recommendations on the use of hypofractionated radiation therapy for patients with localized prostate cancer.

October 30, 2026

Vol.52 No.40

Clinical Roundup

Perioperative apalutamide in high-risk localized or locally advanced prostate cancer substudy supports reduced risk of metastasis and death

An international phase III clinical trial that treated patients with high-risk localized and locally advanced prostate cancer with apalutamide—a next-generation neoadjuvant androgen-receptor pathway inhibitor—plus hormone therapy before and after prostate cancer surgery, was further validated by a substudy demonstrating a reduced risk of metastasis or death compared with standard of care.

October 30, 2026

Vol.52 No.40

Drugs & Targets

FDA expands approval of Talzenna + Xtandi for an earlier metastatic prostate cancer treatment setting

FDA has expanded approval of Talzenna (talazoparib) in combination with Xtandi (enzalutamide) for the treatment of men with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with homologous recombination repair gene mutations, including both BRCA and non-BRCA mutations.

October 30, 2026

Vol.52 No.40

Clinical Roundup

Decipher prostate test predicts benefit from adding hormone therapy to radiation, phase III trial shows

Decipher Prostate Genomic Classifier can predict which patients are more likely to benefit from adding short-term ADT, or androgen deprivation therapy, to dose-escalated radiation, providing both Level 1B1 prognostic and predictive evidence, according to a retrospective ancillary analysis of the randomized phase III NRG/RTOG 0815 trial.

October 02, 2026

Vol.52 No.36

Cancer Policy

Pentagon temporarily rescinds guidance on testosterone testing for U.S. military

The Pentagon has temporarily rescinded a recently published guidance that would require all military personnel aged 30 and over to receive testosterone level testing to check for deficiencies.

September 11, 2026

Vol.52 No.33

By Claire Marie Porter

In Brief

Andrew Hsieh named Larry and Virginia Gordon Endowed Chair in Prostate and Bladder Cancer Research at Fred Hutch

Andrew Hsieh, who serves as the associate director of Fred Hutch’s Human Biology Division, has been named the inaugural holder of the Larry and Virginia Gordon Endowed Chair in Prostate and Bladder Cancer Research.

September 11, 2026

Vol.52 No.33

Xtandi + ADT slow disease-progression in mHSPC compared to darolutamide + ADT

YOU MAY BE INTERESTED IN

ASTRO updates guideline on shorter-course radiation therapy for localized prostate cancer

Perioperative apalutamide in high-risk localized or locally advanced prostate cancer substudy supports reduced risk of metastasis and death

FDA expands approval of Talzenna + Xtandi for an earlier metastatic prostate cancer treatment setting

Decipher prostate test predicts benefit from adding hormone therapy to radiation, phase III trial shows

Pentagon temporarily rescinds guidance on testosterone testing for U.S. military

Andrew Hsieh named Larry and Virginia Gordon Endowed Chair in Prostate and Bladder Cancer Research at Fred Hutch

Renew today!

Subscriber content

Never miss an issue!

Login